EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study

Yujun Hu, Tianzhu Lu iD, Hao Zhang, Bijuan Chen, Jianji Pan, Jingao Li, Xiaochang Gong, Hui Li, Yingying Huang, Nian Lu, Yujing Liang, Liangru Ke und 1 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35382 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yujun Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the efficacy, optimal duration, and target population for maintenance immunotherapy (MI) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) who have achieved disease control following systemic treatment. A multicenter retrospective cohort study included 258 patients whose disease was controlled after chemoimmunotherapy and locoregional radiotherapy. The primary outcome was progression‐free survival (PFS), with conditional survival and restricted mean survival time (RMST) analyses used to determine the optimal MI duration. Immune infiltration was assessed via multiplex immunohistochemistry. The results showed that the 2‐year PFS was significantly higher in the MI group compared to the non‐MI group (69.7% vs. 53.5%, p = .02). Multivariable analysis showed MI was an independent predictor of improved PFS (HR: 0.581, p = .006). Conditional survival and RMST analyses confirmed a significant improvement in PFS with MI continuation within 15 months. Patients with high densities of CD3+ T cells (HR: 0.546, p = .023), CD20+ B cells (HR: 370, p < .001), and a high percentage of PD‐L1+ tumor cells (HR: 0.440, p = .006) had significantly better PFS compared to those with lower levels. Furthermore, MI was particularly beneficial for patients with lower densities of CD3+ T cells ( p = .018), CD20+ B cells ( p < .001), and lower PD‐L1+ tumor cell percentages ( p < .001), while this benefit was not observed in patients with higher immune infiltration levels. In conclusion, a 15‐month duration of MI significantly improves PFS in patients with dmNPC after systemic treatment. Patients with lower levels of immune infiltration tend to have poorer PFS but appear to gain greater benefit from MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsImmunotherapyHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAgedProgression-Free SurvivalChemoradiotherapy

Stichwörter der Autor:innen

de novo metastatic nasopharyngeal carcinomaimmune infiltrationmaintenance immunotherapyoptimal duration

Autor:innen und Institutionen

  • Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
  • Department of Radiation Oncology, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Key Laboratory of Oncology, Jiangxi Cancer Hospital, Nanchang, China.
  • Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Tianzhu Lu, Chuanmiao Xie

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, Y., Lu, T., Zhang, H., Chen, B., Pan, J., Li, J., Gong, X., Li, H., Huang, Y., Lu, N., Liang, Y., Ke, L., & Xie, C. (2025). Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.35382

Vancouver

Hu Y, Lu T, Zhang H, Chen B, Pan J, Li J, et al. Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study. International Journal of Cancer. 2025. doi:10.1002/ijc.35382

BibTeX
@article{Hu2025,
  author = {Hu, Yujun and Lu, Tianzhu and Zhang, Hao and Chen, Bijuan and Pan, Jianji and Li, Jingao and Gong, Xiaochang and Li, Hui and Huang, Yingying and Lu, Nian and Liang, Yujing and Ke, Liangru and Xie, Chuanmiao},
  title = {Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35382}
}
Kostenlos starten →